|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1399 NEW YORK AVE, NW, SUITE 725 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 309071-12
|
||||||||
|
6. House ID# 384420000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Leslie Higgins, Director, Federal Government Relations |
Date | 04/20/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1 the American Recovery and Reinvestment Act of 2009- Title IV, all provisions relating to Health Information Technology, Title V, all provisions relating to Medicaid FMAP; S. 391/HR. 1321 the Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities;
H.R. 816 the Military Retirees Health Care Protection Act, Section 3, all provisions relating to a prohibition on increasing the cost sharing requirement under the pharmacy benefits program and a prohibition on increasing premiums under TRICARE; Medicaid reimbursement for generic drugs relating to accurately defining Average Manufacturers Price (AMP) to reflect purchase price of retail pharmacies to ensure appropriate reimbursement no specific legislation; S. 80 the Pharmaceutical Market Access Act of 2009, all provisions; regarding amending the federal food, drug and cosmetic act to allow pharmacies to import qualifying drugs from certain countries into the United States; S. 525/H.R. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions regarding amending the federal food, drug and cosmetic act to allow the importation of prescription drugs by pharmacies; MedGuides regarding improvement needed to the Medication Guide Program no specific legislation; Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish a workable rule that would allow for electronic prescribing of controlled substances no specific legislation; H.R. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to drug and device safety; H.R. 570 the Protecting Patients and Health Care Act of 2009 all provisions regarding nullifying regulations issued by the Secretary of Health and Human Services regarding conscience clause protections for health care workers and facilities; H.R. 1548 the Pathway for Biosimilars Act all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biopharmaceuticals; S. 726/H.R. 1427 the Promoting Innovation and Access to Life-Saving Medicine Act - all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biopharmaceuticals.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Leslie |
Higgins |
|
|
|
Heather |
Smith |
|
|
|
Susie |
Schulte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
H.R. 759 - the "Food and Drug Administration Globalization Act of 2009" - Title II - Drug and Device Safety - provisions relating to country of origin labeling for drugs and devices;
H.R. 1815 the Consumer Product Safety Solutions Act Section 2 provisions relating to lead limits and third party testing requirements, Section 3 provisions relating to phthalates prohibition, Section 4 provisions relating to clarification of testing methodologies, Section 5 provisions relating to the exclusion of certain materials from lead content limit, Section 6 provisions relating to the waiver of third party testing requirements for certain component parts, Section 7 provisions relating to exemptions from tracking label requirements, Section 8- provisions relating to the general application and exemptive authority of the Consumer Product Safety Commission.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Higgins |
|
|
|
Heather |
Smith |
|
|
|
Susie |
Schulte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
H.R. 1173 the Organized Retail Crime Act of 2009 all provisions, regarding amending title 18 of the United States Criminal Code to include organized retail crime and imposing requirements on on-line marketplaces to aid in criminal investigations; S. 470 the Combating Organized Retail Crime Act of 2009 all provisions, regarding amending the criminal code and expanding the definition of transporting and selling stolen goods from a physical or on-line marketplace;
H.R. 1166 the E-Fencing Enforcement Act of 2009 all provisions, regarding amending the criminal code to impose duty on on-line marketplaces to retain contact information on high volume sellers and disclose that information when evidence is presented by law enforcement regarding stolen merchandise.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Higgins |
|
|
|
Heather |
Smith |
|
|
|
Susie |
Schulte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.701 the Medicare Patient IVIG Access Act of 2009 Section 4, provisions relating to coverage of home administration of IVIG and reimbursement for services, supplies and equipment; Medication Therapy Management (MTM) - program enhancements in the Medicare Modernization Act no specific legislation;
H.R. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease; H.R. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement imposed on suppliers of durable medical equipment; H.R. 574/S. 254 - the "Medicare Home Infusion Therapy Coverage Act of 2009" - all provisions regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Higgins |
|
|
|
Susie |
Schulte |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Healthcare reform - regarding how Walgreens and its subsidiaries can impact efforts in health care reform with regards to access, affordability and quality.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Leslie |
Higgins |
|
|
|
Heather |
Smith |
|
|
|
Susie |
Schulte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |